• Customer Care
  • (888) 123-4567

News

At Rise Therapeutics, we are advancing oral precision immunotherapy, developing first-in-class immune modulatory drugs. Our breakthrough therapies target inflammation, autoimmunity, and cancer, offering innovative, patient-friendly solutions to transform treatment paradigms. Stay tuned for the latest updates on our clinical progress, partnerships, and scientific advancements as we push the boundaries of oral immune therapy.

Rise Therapeutics Receives Seed Funding from Maryland Technology Development Corporation (TEDCO)

Rockville, MD. Rise Therapeutics, a biotechnology company that develops microbiome-based immunological drugs using a unique and proprietary oral biologics delivery platform, announced today that it received seed funding from Maryland Technology Development Corporation (TEDCO). TEDCO is an early-stage funding hub that supports entrepreneurs and drives technology transfer and commercialization in the state of Maryland. 

TEDCO Invests $800,000 into Innovative Tech and Life Science Startups

The Maryland Technology Development Corporation (TEDCO) announced today that six companies received a total of $800,000 in seed funding. 

“At TEDCO, our mission is to foster entrepreneurship and innovation across all regions of the state and we aim to discover, invest in and build great companies that grow, stay and last in Maryland,” stated TEDCO CEO George Davis. “TEDCO helps entrepreneurs bring innovation to market by being the connective tissue to all available assets in the ecosystem, including capital and business development tools.” 

Virtici Announces a New Spin-Out, Rise Therapeutics, Focused on Microbiome Platform Technologies for the Development of Immunological-Based Therapies

Virtici, LLC announced today the spin-out of a new drug development company, Rise Therapeutics, which is focused on developing microbiome-based, immunological therapies. To form the spin-out, Rise obtained key microbiome-related intellectual property and technologies incubated at Virtici to support the development of first-in-class, orally-delivered, biological medicines.